RxDoctor Payments Data

Catherine Murphy

Acute Care · Mechanicsville, VANPI 1346448495

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,910 of the $5,674 with a category attached, or 86.5%. It is spread thinly across 28 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,674in general payments, 2019–2025

Across 162 payments — averaging $35.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Johnson & Johnson$743
  • AstraZeneca$584
  • Boehringer Ingelheim$535
  • Amgen$383
  • Boston Scientific$278
  • plus $2K from 22 others

What the payments were for

  • Speaking & faculty fees$75013%
  • Food & beverage$4,91087%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,674 in reported general payments places this provider in the 90th percentile of 599 acute care providers in Virginia.

See all acute care providers in Virginia

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan58$66,663
EliquisApixaban49$55,446
XareltoRivaroxaban19$29,648
FarxigaDapagliflozin Propanediol14$12,967
Midodrine Hcl23$1,418
Metoprolol Succinate137$1,354
Losartan Potassium112$673
Amlodipine Besylate117$640
Flecainide Acetate22$526
ClopidogrelClopidogrel Bisulfate48$442
Valsartan23$428
Dilt-XrDiltiazem Hcl14$398
Dofetilide11$395
Amiodarone Hcl12$342
Lisinopril43$331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$214$66,66358 claims
PfizerEliquis$192$55,44649 claims
Johnson & JohnsonXarelto$743$29,64819 claims
AstraZenecaFarxiga$584$12,96714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 599 acute care providers in Virginia.

Other acute care in Mechanicsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →